Fisher & Paykel Healthcare (ASX:FPH) Tariff Resilience Score: 6/10 (As of Jun. 30, 2026)


ASX:FPH Fisher & Paykel Healthcare Corp Ltd ASX:FPH
90 GF Score
Price A$32.05
GF Value A$36.41
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Fisher & Paykel Healthcare Tariff Resilience Score?

Fisher & Paykel Healthcare ASX:FPH +0.19% 90 Tariff Resilience Score is 6 as of Jun. 30, 2026. GuruFocus rates ASX:FPH with a GF Score™ of 90/100 and a GF Value™ of A$36.41 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 838 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 91.05% on this metric.

Fisher & Paykel Healthcare has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Fisher & Paykel Healthcare has Global supply chain with manufacturing in New Zealand and sales worldwide. Some exposure to tariffs, but mitigated by diversified markets and strong pricing power.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Fisher & Paykel Healthcare might have Average Resilient.

Fisher & Paykel Healthcare  (ASX:FPH) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Fisher & Paykel Healthcare Tariff Resilience Score Related Terms

ASX:FPH vs ISRG, BDX, MDLN: Tariff Resilience Score Comparison

For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fisher & Paykel Healthcare Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Fisher & Paykel Healthcare's Tariff Resilience Score falls into.


ASX:FPH
90GF Score
Fisher & Paykel Healthcare Corp Ltd ASX:FPH
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Fisher & Paykel Healthcare (ASX:FPH) has a Tariff Resilience Score of 6 as of Jun. 30, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #75 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 8.9%.
Is Fisher & Paykel Healthcare's Tariff Resilience Score too high?
Fisher & Paykel Healthcare's current Tariff Resilience Score is 6. Based on the distribution chart, Fisher & Paykel Healthcare ranks #75 out of 838 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's Tariff Resilience Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #75 out of 838 companies for Tariff Resilience Score. This places Fisher & Paykel Healthcare in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Fisher & Paykel Healthcare's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Modestly Undervalued. The stock's GF Value™ is A$36.41, compared to a current price of A$32.05 — trading 12% below its estimated fair value. The current Tariff Resilience Score is 6. Fisher & Paykel Healthcare's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current Tariff Resilience Score is 6 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?

Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued. The current stock price of A$32.05 is trading 12% below its estimated GF Value™ of A$36.41. GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.

Key valuation signals for ASX:FPH:

  • Tariff Resilience Score: 6
  • GF Value™: A$36.41 vs. price of A$32.05 (12% below fair value)
  • GF Score™: 90/100 with 2 warning signs

No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fisher & Paykel Healthcare Business Description

Other Exchanges FSPKF:USAFPH:New Zealand
Address 15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
90GF Score

Get the complete analysis for ASX:FPH

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$32.05
Price
A$36.41
GF Value